RG Kremer

Medicine 5

Head of Department:
Prof. Dr. med. Andreas Mackensen
Team RG Kremer

Dr. Dr. Anita Kremer, Judith Bausenwein, Anna-Luise Bernhardt, Anna Stueven, Miriam Maierhofer, Sascha Kretschmann

Core area of research:

Our research group mainly focusses on T-cell based immunotherapy of malignant tumors. The emphasis is thereby placed on intracellular processing mechanisms of MHC class II restricted Antigens and identification of neoantigens in solid Tumors. Furthermore, we are working on both aspects also in the context of autoimmune disease.

Current projects:

  • CD4+ T-cell mediated eradication of MHC class II negative tumors via indirect antigen presentation and the underlying intracellular mechanism
  • Separation of Graft-versus-Host disease and Graft-versus-Leukemia effect after allogeneic stem cell transplantation by way of cell type specific processing of MHC class II restricted antigens
  • Identification of neoantigens in patients with breast cancer
  • Identification of autoantigens in autoimmune liver disease
  • Role of MHC class II processing in the development of type 1 diabetes mellitus 
  • The influence of polymorphisms within the hemoxygenase-1 promotor on the expression of the enzyme and its effects on the outcome of allogeneic stem cell transplantation

Selected Publication

Stumpf AN, van der Meijden ED, van Bergen CA, Willemze R, Falkenburg JH, Griffioen M. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood. 2009 Oct 22;114(17):3684-92.

Stevanović S, Griffioen M, Nijmeijer BA, van Schie ML, Stumpf AN, Rutten CE, Willemze R, Falkenburg JH.Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia. Leukemia. 2012 Feb; 26(2):312-22.

Kremer AN, van der Meijden ED, Honders MW, Wiertz EJHJ, Falkenburg JHF, Griffioen M. Endogenous HLA-class-II epitopes that are immunogenic in vivo show distinct behavior towards HLA-DM and its natural inhibitor HLA-DO. Blood. 2012 Oct 18;120(16):3246-55.

Publication Medizin 5

PD Dr. med. Anita Kremer
e-mail: anita.kremer@uk-erlangen.de
business card

Research-Report 2019